The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?

Sponsor
Hartford Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT00282711
Collaborator
GE Healthcare (Industry)
824
43
78
19.2
0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to compare two types of exercise stress testing to find the best method for detecting heart disease in women.

Detailed Description

Coronary artery disease remains the leading cause of morbidity and mortality in women accounting for more than 250,000 deaths per year. While mortality rates have decreased significantly in men during the last several decades, there has been little change for women. Furthermore, despite the high prevalence of ischemic heart disease (IHD) in women, most clinical trials have focused on male cohorts, resulting in a lack of data for women. Their exclusion from clinical trials has been primarily due to the following: 1) child- bearing potential, 2) beyond the arbitrary age limits established for trials, 3) frequent concomitant or advanced disease, and 4) inhomogeneity within the study population.

Extrapolation of the published clinical trial data (predominately obtained in men) for women is controversial due to differences in epidemiology of heart disease in women. Treatment is often sought later in life and is usually accompanied by more advanced disease and co-morbidities, which therefore, impact survival. In addition, women more frequently have an absence of clinical symptoms or an atypical presentation, making the diagnosis of coronary artery disease (CAD) challenging. Furthermore, women may also have their first manifestation of CAD as sudden death or acute myocardial infarction. Therefore, there is a clear need for the early identification of IHD in women so that treatments may be employed prior to having an advanced state of disease and higher risk for unfavorable outcomes.

The optimal non-invasive test for evaluation of IHD in women is unknown. A number of different modalities have been employed including exercise ECG stress testing, 2-dimensional stress echocardiography, single photon emission computerized tomography (SPECT) myocardial perfusion imaging, and electron beam tomography. Additionally, the cohort of women for whom testing is performed is also ill defined.

The most recent AHA/ACC guidelines suggest that ECG stress testing should be the preferred approach. Supportive data for this recommendation are controversial, as many of the studies examining the diagnostic value of ECG stress testing were largely performed in small cohorts of women and are dated. These trials indicate that the diagnostic accuracy of stress testing is only fair (sensitivity=32-89%; specificity=41-68%). A recent meta-analysis in 3,874 women demonstrated modest sensitivity and specificity, 62% and 69% respectively, even after adjustment for referral bias (8). Published guidelines have also included a meta-analysis and confirmed a low level (sensitivity=33%) of detection of disease. Additionally, the high rate of false positives, as well as the inability to fully ascertain the extent of disease, therefore limits the potential value of ECG stress testing.

Even though exercise stress testing is supported by recent clinical guidelines, the addition of SPECT myocardial perfusion imaging has independent and incremental diagnostic and prognostic value. Improved diagnostic accuracy has also been noted with perfusion imaging and its ability to predict cardiac events in women is well established. Furthermore, recent data supports the cost-effectiveness of strategies that employ myocardial perfusion imaging in the assessment of women at risk for ICD.

The current AHA/ACC recommendations fail to take into account that women often have limited ability to complete maximal exercise, a problem that is likely due to their older age and more frequent co-morbidities as compared with men. This functional impairment may lead to a lack of ischemia provocation and/or indeterminate exercise testing results. Maximal predicted heart rate, oxygen consumption, and, more commonly, metabolic equivalents (METs) are measures to estimate physical work capacity. The Duke Activity Status Index (DASI) is a simple 12-item questionnaire that estimates peak oxygen consumption. The Duke Activity Status Index (DASI) questionnaire may identify patients who are likely to perform inadequate exercise, which amounts to nearly 40% of all women referred for exercise testing.

The optimal strategy for the evaluation of women with suspected ischemic heart disease is unknown and quite controversial. Several algorithms have been suggested for the evaluation of women with suspected CAD. A recent consensus paper from the American Society of Nuclear Cardiology suggested a strategy that employed perfusion imaging, but provided little evidence to support such a clinical strategy, such as with a prospective clinical trial. The focus of this investigation is to compare different strategies for the assessment of women at intermediate or high clinical risk for IHD and to do so on a prospective, randomized basis. This study is therefore focused on providing a high level of clinical evidence on which to base future recommendations and guidelines for the care of women with heart disease.

Study Design

Study Type:
Observational
Actual Enrollment :
824 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The WOMEN Study: What is the Optimal Method for Ischemia Evaluation in WomeN?"A Multi-Center, Prospective, Randomized Study to Establish the Optimal Method for Detection of CAD Risk in Women at an Intermediate-High Pre-Test Likelihood CAD"
Study Start Date :
Jun 1, 2004
Actual Primary Completion Date :
Dec 1, 2008
Actual Study Completion Date :
Dec 1, 2010

Arms and Interventions

Arm Intervention/Treatment
1

Standard Exercise treadmill test

2

Exercise treadmill testing with nuclear imaging

Outcome Measures

Primary Outcome Measures

  1. To compare 2-year event rates for women capable of performing exercise treadmill testing with normal myocardial perfusion SPECT using Tc-99m tetrofosmin as compared with a negative stress ECG. [2 years]

Secondary Outcome Measures

  1. To evaluate the differential prognostic accuracy of normal exercise myocardial perfusion Tc-99m tetrofosmin SPECT against a normal exercise ECG. [2 years]

  2. To compare the diagnostic sensitivity and specificity of exercise ECG versus exercise ECG-gated Tc-99m tetrofosmin SPECT myocardial perfusion imaging in women who undergo an elective cardiac catheterization. [2 years]

  3. Utility of the DASI questionnaire in determining which women are able to achieve predicted maximal heart rate response with treadmill testing [2 years]

  4. Non-fatal myocardial infarction [2 years]

  5. Unstable angina leading to revascularization [2 years]

  6. Unstable angina with objective evidence of ischemia requiring hospitalization [2 years]

  7. Cardiac death [2 years]

  8. Hospitalization for heart failure [2 years]

  9. Revascularization [2 years]

  10. To provide objective information for developing guidelines for the evaluation of women at intermediate-high likelihood for CAD. [2 years]

  11. A cost-effectiveness analysis will be performed comparing the various evaluation strategies. [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Women 60 years of age and older presenting for the evaluation of chest pain, or other anginal equivalent symptoms while at an intermediate-high pretest risk for IHD
Exclusion Criteria:
  • Women with known CAD

  • Women scoring <5 METs on the DASI

  • Nursing or pregnant females

  • Nuclear medicine study within the preceding 10 days

  • Electrocardiographic abnormalities precluding interpretation of peak stress changes including: Left bundle branch block, electronic ventricular pacemaker, left ventricular hypertrophy, WPW, and resting ST-T wave changes. Additionally, patients currently on digoxin therapy

  • Significant valvular heart disease (i.e. severe aortic stenosis or regurgitation, or severe mitral insufficiency)

  • Hemodynamic instability (blood pressure >210/110 ml/Hg or <90/60 mm/Hg)

  • Left ventricular systolic dysfunction with a left ventricular ejection fraction less than 30 %

  • Unavailability for long-term follow-up

Contacts and Locations

Locations

Site City State Country Postal Code
1 Southwest Heart Tucson Arizona United States 85715
2 Cardiology Consultants of Orange Country Medical Group, Inc Anaheim California United States 92801
3 Escondido Cardiology Associates Escondido California United States 92025
4 Mission Internal Medical Group Mission Viejo California United States 92691
5 St. Joseph's Hospital Women's Hrt Cnt Orange California United States 92868
6 Sutter Roseville Medical Center Roseville California United States 95661
7 Sacramento Heart & Vascular Res. Ctr. Sacramento California United States 95825
8 San Diego Cardiac Center San Diego California United States 92123
9 Cardiovascular Consultants Walnut Creek California United States 94598
10 Hartford Hospital Hartford Connecticut United States 06102-5037
11 Delaware SPECT Imaging Newark Delaware United States 19713
12 Florida Heart Associates Fort Meyers Florida United States 33907
13 Jacksonville Heart Center, PA Jacksonville Beach Florida United States 32250
14 Diagnostic Cardiology, PA Jacksonville Florida United States 32216
15 Jacksonville Center for Clinical Research Jacksonville Florida United States 32216
16 Jacksonville Heart Center, PA Jacksonville Florida United States 32250
17 Heart and Vascular Institute of Florida St Petersburg Florida United States 33701
18 Cardiac Disease Specialists Atlanta Georgia United States 30309
19 Idaho Cardiology Associates Boise Idaho United States 83704
20 Idaho Cardiology Associates Meridian Idaho United States 83704
21 Fox Valley Cardiovascular Consultants Aurora Illinois United States 60504
22 Saint Francis Hospital of Evanston Evanston Illinois United States 60202
23 Condell Medical Center Libertyville Illinois United States 60048
24 Iowa Heart Center Des Moines Iowa United States 50314
25 Cardiovascular Associates Louisville Kentucky United States 40205
26 Clinical Trials Management, LLC Metairie Louisiana United States 70006
27 Androscoggin Cardiology Associates Auburn Maine United States 04210
28 Cardiovascular Consultants of Maine, PA Scarborough Maine United States 04074
29 Pentucket Medical Associates Haverhill Massachusetts United States 01830
30 Cardiology Associates of Northern Mississippi Tupelo Mississippi United States 38801
31 Cardiovascular Consultants, PC Kansas City Missouri United States 64111
32 Albany Associates in Cardiology Albany New York United States 12212
33 Brooklyn Nuclear SPECT Imaging Brooklyn New York United States 11235
34 Mid-Valley Cardiology Kingston New York United States 12401
35 North Shore University Hospital Manhasset New York United States 11030
36 Blue Stem Cardiology Bartlesville Oklahoma United States 74006
37 Cardiology Consultants of Philadelphia Philadelphia Pennsylvania United States 19146
38 Cardiology Consultants of Philadelphia Philadelphia Pennsylvania United States 19148
39 Medical University of SC (MUSC) Charleston South Carolina United States 29466
40 Heart Place Dallas Texas United States 75226
41 Deaconess Medical Center Spokane Washington United States 99204
42 Univ. of Ottawa Heart Insitute Ottawa Ontario Canada K1Y4W7
43 Sudbury Regional Hospital Sudbury Ontario Canada P3E 6C3

Sponsors and Collaborators

  • Hartford Hospital
  • GE Healthcare

Investigators

  • Principal Investigator: Gary V. Heller, M.D., Ph.D., Hartford Hospital, Hartford, CT
  • Principal Investigator: Robert C. Hendel, M.D., Rush University Medical Center, Chicago, IL
  • Principal Investigator: Jennifer H. Mieres, M.D., North SHore University Hospital, Long Island, NY
  • Principal Investigator: Leslie J. Shaw, Ph.D., Atlanta Cardiovascular Research Institute, Atlanta, GA

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Hartford Hospital
ClinicalTrials.gov Identifier:
NCT00282711
Other Study ID Numbers:
  • HELL001524HE
  • The WOMEN study
First Posted:
Jan 27, 2006
Last Update Posted:
Aug 1, 2012
Last Verified:
Jul 1, 2012

Study Results

No Results Posted as of Aug 1, 2012